drugset / Trial / NCT02315287

Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management

NCT02315287

Phase 4 Unknown 190 enrolled Seoul National University Bundang Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Triple combination of metformin, DPP4 inhibitor and Thiazolidinedione would be a good option in the treatment of drug-naïve Korean type 2 diabetic patients. Newly developed thiazolidinedione, Lobeglitazone would be not inferior to Pioglitazone.

Timeline

Start
2014-09
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lobeglitazone Small molecule
Comparator Pioglitazone Small molecule